Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer
chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP …

Multidrug resistance (MDR) is a major cause of failure in cancer chemotherapy. P-
glycoprotein (P-gp), a promiscuous drug efflux pump, has been extensively studied for its …

The presence of multidrug resistance (MDR) in malignant tumors is one of the primary
causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding …

One of the major causes of failure in cancer chemotherapy is multidrug resistance (MDR),
where cancer cells simultaneously become resistant to different anticancer drugs. Over …

This year marks the 30th anniversary of the discovery of the multidrug resistance (MDR) ATP-
binding cassette (ABC) transporter P-glycoprotein (P-gp). Since then a considerable …

Multidrug resistance (MDR) seriously limits the clinical application of chemotherapy. A
mechanism underlying MDR is the overexpression of efflux transporters associated with …

Cancer patients who receive chemotherapy often experience intrinsic or acquired resistance
to a broad spectrum of chemotherapeutic agents. The phenomenon, termed multidrug …

P-glycoprotein (P-gp) is a key player in the multidrug-resistant phenotype in cancer. The
protein confers resistance by mediating the ATP-dependent efflux of an astonishing array of …

Multidrug resistance (MDR) in cancer chemotherapy is a growing concern for medical
practitioners. P-glycoprotein (P-gp) overexpression is one of the major reasons for multidrug …

The emergence of multidrug resistance (MDR) in malignant tumors is one of the leading
threats encountered currently in many chemotherapeutic agents. The overexpression of the …